Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL - Get Free Report) updated its FY 2025 earnings guidance on Saturday. The company provided earnings per share (EPS) guidance of 1.000-1.650 for the period, compared to the consensus estimate of 1.770. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.

Analyst Ratings Changes

Several brokerages have commented on OMCL. Benchmark lowered their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research report on Saturday, May 3rd. Wells Fargo & Company upgraded Omnicell from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $31.00 to $35.00 in a report on Wednesday. Finally, JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a report on Thursday, March 20th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Omnicell has an average rating of "Hold" and a consensus target price of $46.50.

Omnicell Price Performance

Shares of Omnicell stock opened at $27.96 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The business's 50 day simple moving average is $31.41 and its two-hundred day simple moving average is $39.55. The stock has a market capitalization of $1.31 billion, a P/E ratio of 103.56, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The business's revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share. Analysts forecast that Omnicell will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Omnicell

An institutional investor recently raised its position in Omnicell stock. AQR Capital Management LLC raised its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 42.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,936 shares of the company's stock after acquiring an additional 5,311 shares during the period. AQR Capital Management LLC's holdings in Omnicell were worth $627,000 as of its most recent SEC filing. Institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.